Evaluation of Azathioprine versus Mycophenolate Mofetil as a Steroid Sparing Agent in the Treatment of Pemphigus Vulgaris

Background: Pemphigus vulgaris (PV) is a life-threatening autoimmune bullous disease characterized by flaccid blisters and erosions of the skin and mucous membranes due to acantholysis. The severity of diseases stems from their progressive nature, leading to increased body catabolism, loss of body fluids and proteins, and secondary bacterial and viral infections that can result in sepsis and cardiac failure. Objective: To compare the efficacies of azathioprine versus mycophenolate mofetil as a steroid-sparing agent in the treatment of pemphigus vulgaris. Methods: This comparative study was conducted in the Department of Dermatology and Venereology at Combined Military Hospital, Dhaka from April 2016 to September 2016. As the study subjects, 60 adult pemphigus vulgaris patients were enrolled and divided into two groups; Group A received oral mycophenolate mofetil (1.5 gm daily) for 12 weeks, while Group B received azathioprine (2.5 mg/kg/day) for the same period. Data were analyzed using SPSS v23.0. Results: Baseline sociodemographic and clinical characteristics were similar between Group A and Group B, with no significant differences in age, sex, marital status, disease duration or family history of pemphigus vulgaris. Both groups exhibited progressive clinical improvement over time. Group A achieved a significantly greater reduction in mean PDAI score at 12 weeks (14.2±7.1 vs 19.7±8.4, p=0.008) and at 24 weeks (6.8±5.9 vs 12.4±7.0, p=0.001). Mean severity scores declined in both groups, with lower final scores observed in Group A (0.57±0.76 vs 1.00±0.96), although this difference did not reach statistical significance (p=0.059). Adverse effects were reported in both groups, with gastrointestinal disturbances more prevalent in Group A and hematologic complications more frequent in Group B. Conclusion: Mycophenolate mofetil is slightly more efficacious than azathioprine. It can serve as a good alternative for the treatment of pemphigus vulgaris as a steroid-sparing agent, provided the individual can afford this drug due to its high cost and relatively fewer side effects. JAFMC Bangladesh, Vol-22, No-1, June 2026:23-27

Authors

Publication Details

Journal
Journal of Armed Forces Medical College Bangladesh
Published
2026-11-12
DOI
https://doi.org/10.3329/jafmc.v22i1.89813
Primary Topic
Autoimmune Bullous Skin Diseases
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Evaluation of Azathioprine versus Mycophenolate Mofetil as a Steroid Sparing Agent in the Treatment of Pemphigus Vulgaris

Md Moshiur Rahman
Journal of Armed Forces Medical College Bangladesh
Autoimmune Bullous Skin Diseases
article

Evaluation of Azathioprine versus Mycophenolate Mofetil as a Steroid Sparing Agent in the Treatment of Pemphigus Vulgaris

Md Moshiur Rahman
article en

Abstract

Background: Pemphigus vulgaris (PV) is a life-threatening autoimmune bullous disease characterized by flaccid blisters and erosions of the skin and mucous membranes due to acantholysis. The severity of diseases stems from their progressive nature, leading to increased body catabolism, loss of body fluids and proteins, and secondary bacterial and viral infections that can result in sepsis and cardiac failure. Objective: To compare the efficacies of azathioprine versus mycophenolate mofetil as a steroid-sparing agent in the treatment of pemphigus vulgaris. Methods: This comparative study was conducted in the Department of Dermatology and Venereology at Combined Military Hospital, Dhaka from April 2016 to September 2016. As the study subjects, 60 adult pemphigus vulgaris patients were enrolled and divided into two groups; Group A received oral mycophenolate mofetil (1.5 gm daily) for 12 weeks, while Group B received azathioprine (2.5 mg/kg/day) for the same period. Data were analyzed using SPSS v23.0. Results: Baseline sociodemographic and clinical characteristics were similar between Group A and Group B, with no significant differences in age, sex, marital status, disease duration or family history of pemphigus vulgaris. Both groups exhibited progressive clinical improvement over time. Group A achieved a significantly greater reduction in mean PDAI score at 12 weeks (14.2±7.1 vs 19.7±8.4, p=0.008) and at 24 weeks (6.8±5.9 vs 12.4±7.0, p=0.001). Mean severity scores declined in both groups, with lower final scores observed in Group A (0.57±0.76 vs 1.00±0.96), although this difference did not reach statistical significance (p=0.059). Adverse effects were reported in both groups, with gastrointestinal disturbances more prevalent in Group A and hematologic complications more frequent in Group B. Conclusion: Mycophenolate mofetil is slightly more efficacious than azathioprine. It can serve as a good alternative for the treatment of pemphigus vulgaris as a steroid-sparing agent, provided the individual can afford this drug due to its high cost and relatively fewer side effects. JAFMC Bangladesh, Vol-22, No-1, June 2026:23-27

Journal of Armed Forces Medical College BangladeshVol. 22(1)
Good health and well-being
Autoimmune Bullous Skin Diseases
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon